Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3

被引：4

作者：

Martinez-Lopez, Joaquin ^{[1
]}

Castro, Nerea ^{[1
]}

Rueda, Daniel ^{[1
]}

Canal, Alicia ^{[1
]}

Grande, Carlos ^{[1
]}

Ayala, Rosa ^{[1
]}

机构：

[1] Univ Complutense Madrid, Hosp Univ Doce Octubre, Div Hematol, Madrid, Spain

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 158卷 / 04期

关键词：

acute myeloid leukaemia; FLT3; mutations; Sorafenib; ACUTE MYELOID-LEUKEMIA; TANDEM DUPLICATION; RECEPTOR;

D O I：

10.1111/j.1365-2141.2012.09189.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：555 / 558

页数：4

共 10 条

[1] Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia [J].

Abu-Duhier, FM ;

Goodeve, AC ;

Wilson, GA ;

Care, RS ;

Peake, IR ;

Reilly, JT .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) :983-988

[2] A novel point mutation within the juxtamembrane domain of the flt3 gene in acute myeloid leukemia [J].

Gianfelici, Valentina ;

Diverio, Daniela ;

Breccia, Massimo ;

Buffolino, Sonia ;

Derme, Valentina ;

Di Lascio, Attilio ;

Marinelli, Marilisa ;

Santangelo, Simona ;

Meloni, Giovanna ;

Foa, Robin .

ANNALS OF HEMATOLOGY, 2011, 90 (07) :845-846

[3] The structural basis for autoinhibition of FLT3 by the juxtamembrane domain [J].

Griffith, J ;

Black, J ;

Faerman, C ;

Swenson, L ;

Wynn, M ;

Lu, F ;

Lippke, J ;

Saxena, K .

MOLECULAR CELL, 2004, 13 (02) :169-178

[4] Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor β receptor [J].

Irusta, PM ;

Luo, Y ;

Bakht, O ;

Lai, CC ;

Smith, SO ;

DiMaio, D .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (41) :38627-38634

[5] Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation [J].

Metzelder, Stephan ;

Wang, Ying ;

Wollmer, Ellen ;

Wanzel, Michael ;

Teichler, Sabine ;

Chaturvedi, Anuhar ;

Eilers, Martin ;

Enghofer, Erich ;

Neubauer, Andreas ;

Burchert, Andreas .

BLOOD, 2009, 113 (26) :6567-6571

[6] Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia [J].

Mohan, Babu P. ;

How, Gee-fung ;

Loh, Yvonne ;

Linn, Yeh-ching .

BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (01) :131-132

[7]

Nakao M, 1996, LEUKEMIA, V10, P1911

[8] Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML [J].

Reindl, C ;

Bagrintseva, K ;

Vempati, S ;

Schnittger, S ;

Ellwart, JW ;

Wenig, K ;

Hopfner, KP ;

Hiddemann, W ;

Spiekermann, K .

BLOOD, 2006, 107 (09) :3700-3707

[9] Detection of NPM1 exon 12 mutations and FLT3-internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia [J].

Tan, Angela Y. C. ;

Westerman, David A. ;

Carney, Dennis A. ;

Seymour, John F. ;

Juneja, Surender ;

Dobrovic, Alexander .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2008, 1 (1)

[10] BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [J].

Wilhelm, SM ;

Carter, C ;

Tang, LY ;

Wilkie, D ;

McNabola, A ;

Rong, H ;

Chen, C ;

Zhang, XM ;

Vincent, P ;

McHugh, M ;

Cao, YC ;

Shujath, J ;

Gawlak, S ;

Eveleigh, D ;

Rowley, B ;

Liu, L ;

Adnane, L ;

Lynch, M ;

Auclair, D ;

Taylor, I ;

Gedrich, R ;

Voznesensky, A ;

Riedl, B ;

Post, LE ;

Bollag, G ;

Trail, PA .

CANCER RESEARCH, 2004, 64 (19) :7099-7109

← 1 →